» Articles » PMID: 9559737

Ocular Manifestations of Giant Cell Arteritis

Overview
Journal Am J Ophthalmol
Specialty Ophthalmology
Date 1998 Apr 29
PMID 9559737
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To report the ocular manifestations of giant cell arteritis using the strict criterion of a positive temporal artery biopsy for diagnosis of giant cell arteritis.

Methods: In a prospective study from 1973 to 1995, we investigated 170 patients whose diagnosis of giant cell arteritis was confirmed on temporal artery biopsy. At the initial visit, all patients were questioned regarding systemic and ocular signs and symptoms of giant cell arteritis and underwent ophthalmic, erythrocyte sedimentation rate (Westergren), and C-reactive protein evaluations. Any patient with a high index of suspicion of giant cell arteritis was immediately started on systemic corticosteroid therapy and had temporal artery biopsy performed as soon as possible.

Results: Eighty-five (50.0%) of the 170 patients with giant cell arteritis proven by temporal artery biopsy presented with ocular involvement. Ocular symptoms in patients with ocular involvement were visual loss of varying severity in 83 (97.7%), amaurosis fugax in 26 (30.6%), diplopia in five (5.9%), and eye pain in seven (8.2%); ocular ischemic lesions consisted of arteritic anterior ischemic optic neuropathy in 69 (81.2%), central retinal artery occlusion in 12 (14.1%), cilioretinal artery occlusion in 12 (of 55 patients with satisfactory fluorescein angiography [21.8%]), posterior ischemic optic neuropathy in six (7.1%), and ocular ischemia in one (1.2%). In almost every patient with giant cell arteritis, fluorescein fundus angiography disclosed occlusive disease of the posterior ciliary arteries.

Conclusion: Because giant cell arteritis is a potentially blinding disease and its early diagnosis is the key to preventing blindness, it is important to recognize its various ocular manifestations.

Citing Articles

Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry.

Molina-Collada J, Dominguez-Alvaro M, Melero-Gonzalez R, De Miguel E, Silva-Diaz M, Valero Jaimes J Arthritis Res Ther. 2025; 27(1):4.

PMID: 39773317 PMC: 11705974. DOI: 10.1186/s13075-024-03468-6.


A case-control study of peripapillary microvascular structure by OCT-angiography in non-arteritic ischaemic optic neuropathy at early and resolutive stages.

Castelain J, Romdhane K, Aptel F, Pollet-Villard F, Attoui O, Bailly S Eye (Lond). 2024; 39(4):771-778.

PMID: 39578548 PMC: 11885533. DOI: 10.1038/s41433-024-03439-w.


The primary systemic vasculitis associated optic neuritis: a retrospective analysis in a single center over 10 years.

Tang S, Zhou H, Li R, Wang Y, Li H, Hou Y Int Ophthalmol. 2024; 44(1):387.

PMID: 39312014 PMC: 11420302. DOI: 10.1007/s10792-024-03307-2.


Giant Cell Arteritis: Updates and Controversies.

Yu E, Chang J Front Ophthalmol (Lausanne). 2024; 2:848861.

PMID: 38983551 PMC: 11182101. DOI: 10.3389/fopht.2022.848861.


Transient Monocular Visual Loss (Amaurosis Fugax): How Does Age Impact Diagnosis?.

Douglas V, Rachapudi S, Davila-Siliezar P, Laylani N, Lee A Ophthalmol Ther. 2024; 13(6):1417-1425.

PMID: 38587773 PMC: 11109035. DOI: 10.1007/s40123-024-00932-z.